Halobetasol cream is a bioequivalent of Bristol-Myers Squibb’s Ultravate cream, a super-high potency prescription topical corticosteroid product used primarily for the treatment of inflammatory skin conditions.
According to industry sources, US sales of halobetasol cream products were approximately $24.7 million in 2004. Taro already markets an ointment version of this product.
Hydrocortisone butyrate cream is a generic version of Ferndale Laboratories’ Locoid cream. The approval of Taro’s abbreviated new drug application to market its version of this cream will give the company access to a US market for Locoid cream thought to be worth approximately $8.2 million in 2004.